gemtuzumab ozogamicin NPM1 Mutation Acute Myeloid Leukemia Newly diagnosed Induction gemtuzumab ozogamicin chemotherapy, +1 more type
SNDX-5613 KMT2A Fusion, +1 more biomarker Acute Leukemia Relapse/refractory SNDX-5613 targeted therapy